Of those cancers that showed decreased risk of GLP-1RAs compared with insulin, risk reduction was also noted for GLP-1RAs relative to metformin for colorectal cancer, gallbladder, and meningiomas, although these findings were not statistically significant. The gene discussed is INS; the disease is colorectal cancer.